SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors

被引：0

作者：

Curioni-Fontecedro, A. ^{[1
]}

Holer, L. ^{[2
]}

Frueh, M. ^{[3
]}

Weindler, S. ^{[4
]}

Konig, D. ^{[5
]}

Addeo, A. ^{[6
]}

Britschgi, C. ^{[7
]}

Rigutto, A. ^{[8
,9
]}

Waibel, C. ^{[10
]}

Bettini, A. ^{[11
]}

Cerciello, F. W. F. ^{[12
]}

Hiltbrunner, S. ^{[9
,13
]}

Nguyen, D. L. ^{[14
]}

Zellweger, C. ^{[15
]}

Musilova, J. ^{[16
]}

Von Moos, R. A. F. ^{[17
]}

Joerger, M. ^{[18
]}

机构：

[1] Univ Zurich Hosp, Dept Oncol, Cantonal Hosp Fribourg, Fribourg, Switzerland

[2] SAKK Swiss Grp Clin Canc Res, Bern, Switzerland

[3] Kantonsspital St Gallen, Dept Oncol, St Gallen, Switzerland

[4] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland

[5] Univ Basel Hosp, Dept Med Oncol, Basel, Switzerland

[6] HUG Hop Univ Geneve, Dept Oncol, Geneva, Switzerland

[7] USZ Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland

[8] Univ Zurich, Fac Sci & Med, Dept Med Surg Specialties, Zurich, Switzerland

[9] Univ Fribourg, Fribourg, Switzerland

[10] Kantonsspital Baden, Med Oncol, Baden, Switzerland

[11] HFR Hop Cantonal, Med Oncol, Fribourg, Switzerland

[12] Univ Klin Med Onkol, Dept Med Oncol, Inselspital, Bern, Switzerland

[13] Univ Zurich Hosp, Fac Sci & Med, Zurich, Switzerland

[14] Stadtsp Zurich Triemli, Dept Radiol & Nucl Med, Zurich, Switzerland

[15] USZ Univ Hosp Zurich, Dept Radiol, Inst Diagnost & Intervent Radiol, Zurich, Switzerland

[16] SAKK Swiss Grp Clin Canc Res, Dept Stat, Bern, Switzerland

[17] KSGR Kantonsspital Graubunden, Dept Hematol Oncol, Chur, Switzerland

[18] Kantonsspital St Gallen, Med Oncol & Hematol Dept, St Gallen, Switzerland

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1412P

引用

页数：2

共 50 条

[1] Circulating Protein Signatures and Immune Cells Are Predictive and Prognostic Markers for Patients with NSCLC in the SAKK 17/18 Trial
Rigutto, A.
Feng, Y.
Shichkova, P.
Raess, L.
Schaer, S.
Bruderer, R.
Tognetti, M.
Joerger, M.
Hayoz, S.
Somasundaram, V.
Nunez, N.
Fournier, N.
Lourenco, J.
Gottardo, R.
Becher, B.
Addeo, A.
Gupta, A.
Curioni-Fontecedro, A.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S88 - S89
[2] A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Jang, H. Josh
Hostetter, Galen
Macfarlane, Alexander W.
Madaj, Zachary
Ross, Eric A.
Hinoue, Toshinori
Kulchycki, Justin R.
Burgos, Ryan S.
Tafseer, Mahvish
Alpaugh, R. Katherine
Schwebel, Candice L.
Kokate, Rutika
Geynisman, Daniel M.
Zibelman, Matthew R.
Ghatalia, Pooja
Nichols, Peter W.
Chung, Woonbok
Madzo, Jozef
Hahn, Noah M.
Quinn, David I.
Issa, Jean-Pierre J.
Topper, Michael J.
Baylin, Stephen B.
Shen, Hui
Campbell, Kerry S.
Jones, Peter A.
Plimack, Elizabeth R.
CLINICAL CANCER RESEARCH, 2023, 29 (11) : 2052 - 2065
[3] Preliminary results of phase II trial with combination of gemcitabine and oxaliplatin in elderly patients with advanced NSCLC.
Buosi, R
Poletti, S
Cantele, V
Piazza, S
Torazzo, R
Negru, E
Vandone, A
Alabiso, O
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 703S - 703S
[4] A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
Ghalib, Mohammad H.
Pulla, Mariano Provencio
Luken, Maria J. De Miguel
de Juan, Virginia Calvo
Chaudhary, Imran
Hammami, M. Bakri
Vikash, Sindhu
Maitra, Radhashree
Martinez, Sara
Kahatt, Carmen
Extremera, Sonia
Fudio, Salvador
Goel, Sanjay
INVESTIGATIONAL NEW DRUGS, 2024, 42 (05) : 481 - 491
[5] Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Patients: A
Zhang, Jian
Zou, Zhonghua
Tan, Jie
Shi, Jianping
Yang, Hui
Wang, Hao
Zhou, Jundong
Xue, Jing
JOURNAL OF CANCER, 2023, 14 (09): : 1623 - 1634
[6] Efficacy and safety of sunitinib in a multicenter phase II trial of previously treated, advanced non-small cell lung cancer (NSCLC)
Socinski, Mark A.
Novello, Silvia
Sanchez, Jose M.
Brahmer, Julie
Govindan, Ramaswamy
Belani, Chandra P.
Atkins, James N.
Gillenwater, Heidi H.
Palleres, C.
Chao, Richard C.
ANNALS OF ONCOLOGY, 2006, 17 : 218 - 218
[7] Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results
Wakelee, Heather
Patel, Jyoti D.
Heist, Rebecca
Balmanoukian, Ani
Besse, Benjamin
Felip, Enriqueta
Carcereny Costa, Enric
Chow, Laura Q.
Koczywas, Marianna
Garassino, Marina C.
Christoph, Daniel
Toh, Chee Keong
Johnson, Melissa L.
Chaft, Jamie
Kurata, Takayasu
Qiu, Jiaheng
Kowanetz, Marcin
Coleman, Shelley
Mocci, Simonetta
Sandler, Alan
Gettinger, Scott N.
Peters, Solange
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S251 - S252
[8] Biweekly carboplatin and gemcitabine for untreated advanced non-small cell lung cancer (NSCLC). A multicenter phase II trial
Domine, M
Gomez, RG
Firvida, J
Delgado, J
Estevez, L
Docampo, LI
Leon, A
Pachon, V
Casado, V
Lobo, F
LUNG CANCER, 2005, 49 : S242 - S242
[9] Clinical benefit and quality of life in patients with advanced biliary tract cancer receiving gemcitabine plus capecitabine (GemCap): Results from a multicenter phase II trial (SAKK 44/02)
Gerber, D.
Dietrich, D.
Koeberle, D.
Saletti, P.
Borner, M.
Caspar, C. B.
Mingrone, W.
Beretta, K.
Herrmann, R.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[10] A multicenter phase II trial with gemcitabine plus oxaliplatin as second line treatment in patients with advanced non-small cell lung cancer (NSCLC).
Kouroussis, C
Syrigos, K
Potamianou, A
Ziras, N
Ziotopoulos, P
Stergiou, J
Ginopoulos, P
Tselepatiotis, E
Biozionelou, V
Georgoulias, V
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 681S - 681S

← 1 2 3 4 5 →